Lineage Cell Therapeutics, Inc. Annual Earnings Per Share, Diluted in USD/shares from 2014 to 2023

Taxonomy & unit
us-gaap: USD/shares
Description
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Summary
Lineage Cell Therapeutics, Inc. quarterly/annual Earnings Per Share, Diluted history and growth rate from 2014 to 2023.
  • Lineage Cell Therapeutics, Inc. Earnings Per Share, Diluted for the quarter ending June 30, 2024 was -0.03 USD/shares, unchanged year-over-year.
  • Lineage Cell Therapeutics, Inc. Earnings Per Share, Diluted for the twelve months ending June 30, 2024 was -0.14 USD/shares, a 7.69% decline year-over-year.
  • Lineage Cell Therapeutics, Inc. annual Earnings Per Share, Diluted for 2023 was -0.12 USD/shares, a 20% increase from 2022.
  • Lineage Cell Therapeutics, Inc. annual Earnings Per Share, Diluted for 2022 was -0.15 USD/shares.
  • Lineage Cell Therapeutics, Inc. annual Earnings Per Share, Diluted for 2017 was -0.17 USD/shares, a 150% decline from 2016.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Annual (USD/shares)
Earnings Per Share, Diluted, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $0 +$0.03 +20% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-07
2022 $0 Jan 1, 2022 Dec 31, 2022 10-K 2024-03-07
2017 $0 -$1 -150% Jan 1, 2017 Dec 31, 2017 10-K 2018-03-15
2016 $0.34 +$0.93 Jan 1, 2016 Dec 31, 2016 10-K 2018-03-15
2015 -$1 $0 -7.27% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-15
2014 -$1 Jan 1, 2014 Dec 31, 2014 10-K 2017-03-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.